Last reviewed · How we verify
NCT02752893
Estrogen Receptor-Positive Breast Cancer Patient-Derived Xenografts
trial in Breast Cancer in 10 participants. Completed in 3 April 2019.
3 April 2019
Quick facts
| Lead sponsor | Dartmouth-Hitchcock Medical Center |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 10 |
| Start date | 30 January 2017 |
| Primary completion | 3 April 2019 |
| Estimated completion | 3 April 2019 |
| Sites | 1 location across United States |
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
Sponsor
Dartmouth-Hitchcock Medical Center
Who can join
18 and older, any sex, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The investigators will establish a platform at Dartmouth-Hitchcock Medical Center to generate novel models of estrogen receptor alpha-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer, which will be used for research studies to develop novel treatment strategies and dissect signaling pathways underlying drug sensitivity and resistance.
Publications & conference data
5 peer-reviewed publications reference this trial (live from Europe PMC):
-
Patient-derived xenograft models in cancer therapy: technologies and applications.
Liu Y, Wu W, Cai C, Zhang H, et al · · 2023 · cited 290× · PMID 37045827 · DOI 10.1038/s41392-023-01419-2 -
Bridging the divide: preclinical research discrepancies between triple-negative breast cancer cell lines and patient tumors.
Sulaiman A, Wang L. · · 2017 · cited 41× · PMID 29348905 · DOI 10.18632/oncotarget.22916 -
Current and Future Horizons of Patient-Derived Xenograft Models in Colorectal Cancer Translational Research.
Inoue A, Deem AK, Kopetz S, Heffernan TP, et al · · 2019 · cited 31× · PMID 31500168 · DOI 10.3390/cancers11091321 -
Patient-derived xenograft model in colorectal cancer basic and translational research.
Liu X, Xin Z, Wang K. · · 2023 · cited 16× · PMID 36543756 · DOI 10.1002/ame2.12299 -
Harnessing PDX and PDX 2.0: the next-generation paradigm for precision oncology and translational breakthroughs.
Jian C, Fu H, Wu W, Zhang N, et al · · 2026 · PMID 41699647 · DOI 10.1186/s12943-026-02594-w
Verify or expand the search:
- PubMed search for NCT02752893
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Other Dartmouth-Hitchcock Medical Center trials
Trials by the same sponsor.
- NCT07325474 — Plan and Protect: Safety Planning for Teens in Rural Emergency Departments · NA · not yet recruiting
- NCT07428629 — Piloting an Insomnia Treatment in Patients With Ulcerative Colitis · NA · not yet recruiting
- NCT06777511 — Advancing Antimicrobial Photodynamic Therapy to Prevent Infection in Osseointegrated Prosthesis Patients · not yet recruiting
- NCT07279116 — ABY-029 Head & Neck Trial · Phase 1 · not yet recruiting
- NCT07063693 — ABY-029 Glioma Trial · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02752893 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Dartmouth-Hitchcock Medical Center
- Last refreshed: 1 June 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02752893.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing